Iovance Biotherapeutics, Inc.

Quick facts

Phase 3 pipeline

• Lifileucel plus Pembrolizumab · Oncology
  Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) therapy that expands patient-derived T cells from their tumor and reinfuses them alongside pembrolizumab, a PD-1 inhibitor, to enhance anti-tumor immune response.
• Pembrolizumab with Optional Crossover Period · Oncology
  Pembrolizumab blocks PD-1 on immune cells to release the brakes on anti-tumor immunity, allowing T cells to recognize and attack cancer cells.

Phase 2 pipeline

• LN-145-S1
• OOS AMTAGVI

Phase 1 pipeline

• IOV-2001
• IOV-3001
• IOV-4001

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Iovance Biotherapeutics, Inc. portfolio CI brief
• Iovance Biotherapeutics, Inc. pipeline updates RSS